Deferiprone in Friedreich ataxia: A 6-Month randomized controlled trial-Reference-Cited by-同舟云学术

Deferiprone in Friedreich ataxia: A 6-Month randomized controlled trial

Published:2014-08-30 Issue:4 Volume:76 Page:509-521
ISSN:0364-5134
Container-title:Annals of Neurology
language:en
Short-container-title:Ann Neurol.

Author:

Pandolfo Massimo¹,Arpa Javier²,Delatycki Martin B.³,Le Quan Sang Kim Hanh⁴,Mariotti Caterina⁵,Munnich Arnold⁴,Sanz-Gallego Irene²,Tai Geneieve³,Tarnopolsky Mark A.⁶,Taroni Franco⁵,Spino Michael⁷,Tricta Fernando⁷

Affiliation:

1. Department of Neurology, Erasme Hospital; Université Libre de Bruxelles; Brussels Belgium

2. Neurology Service; La Paz University Hospital; Madrid Spain

3. Bruce Lefroy Centre for Genetic Health Research; Murdoch Children's Research Institute; Parkville Victoria Australia

4. Necker-Sick Children Hospital Center; Paris France

5. Unit of Genetics of Neurodegenerative and Metabolic Disease; Carlo Besta Neurological Institute, Institute of Hospitalization and Scientific Care Foundation; Milan Italy

6. Division of Neurology, Department of Medicine; McMaster University Medical Centre; Hamilton Ontario Canada

7. ApoPharma; Toronto Ontario Canada

Funder

Apopharma

Publisher

Wiley

Subject

Clinical Neurology,Neurology

Reference37 articles.

1. Friedreich ataxia: the clinical picture;Pandolfo;J Neurol,2009

2. Prevalence gradients of Friedreich's ataxia and R1b haplotype in Europe co-localize, suggesting a common Palaeolithic origin in the Franco-Cantabrian ice age refuge;Vankan;J Neurochem,2013

3. Clinical features of Friedreich's ataxia: classical and atypical phenotypes;Parkinson;J Neurochem,2013